Commentary/Editorials
Section edited by Christian Capitini, MD
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.
- COMMENTARY
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap
Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapi...Journal for ImmunoTherapy of Cancer 2017 5:59Published on: 18 July 2017 - COMMENTARY
Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis
Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However, they have been associated with inflammatory adverse reactions in various organ systems. A recent art...Journal for ImmunoTherapy of Cancer 2017 5:24Published on: 21 March 2017 - COMMENTARY
Immunotherapy resistance: the answers lie ahead – not in front – of us
Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manu...Journal for ImmunoTherapy of Cancer 2017 5:10Published on: 21 February 2017 - COMMENTARY
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Ji...Journal for ImmunoTherapy of Cancer 2017 5:17Published on: 21 February 2017 - COMMENTARY
Potassium channels of T lymphocytes take center stage in the fight against cancer
A recent study by Eil at al. published in Nature in September 2016 provides evidence that alterations of the K+ homeostasis of tumor infiltrating lymphocytes (TILs) in necrotic areas of the tumor microenvironment...Journal for ImmunoTherapy of Cancer 2017 5:2Published on: 17 January 2017 - COMMENTARY
It’s a long way to the top (if you want to personalize immunotherapy)
Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Fol...Journal for ImmunoTherapy of Cancer 2017 5:6Published on: 17 January 2017 - COMMENTARY
Being “penny-wise but pound foolish” in cancer immunotherapy research: the urgent need for mouse cancer models to reflect human modifying factors
Inbred mice are the mainstay for preclinical cancer assessment of potential therapeutics, especially immune-based approaches. However, the use of young, lean, inbred mice housed under specific-pathogen-free co...Journal for ImmunoTherapy of Cancer 2016 4:88Published on: 20 December 2016 - COMMENTARYJournal for ImmunoTherapy of Cancer 2016 4:87Published on: 20 December 2016
- COMMENTARY
Application of the Immunoscore as prognostic tool for hepatocellular carcinoma
To date, the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) tumor, nodes, metastasis (TNM) classification represents the standard system for evaluation of progn...Journal for ImmunoTherapy of Cancer 2016 4:71Published on: 15 November 2016 - COMMENTARYJournal for ImmunoTherapy of Cancer 2016 4:54Published on: 20 September 2016
- COMMENTARYJournal for ImmunoTherapy of Cancer 2016 4:43Published on: 16 August 2016
- COMMENTARY
Circulating protein and antibody biomarker for personalized cancer immunotherapy
Immune checkpoint blockade therapies are revolutionizing standard cancer treatments. Immune checkpoint inhibitors likely function to enhance the tumor specific antigen response in order to achieve favorable cl...Journal for ImmunoTherapy of Cancer 2016 4:46Published on: 16 August 2016 - COMMENTARYJournal for ImmunoTherapy of Cancer 2016 4:42Published on: 19 July 2016
- COMMENTARY
NLRC5, a promising new entry in tumor immunology
The recent use of T cell-based cancer immunotherapies, such as adoptive T-cell transfer and checkpoint blockade, yields increasing clinical benefit to patients with different cancer types. However, decrease of...Journal for ImmunoTherapy of Cancer 2016 4:39Published on: 19 July 2016 - COMMENTARY
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
The recent study by Hodi et al. published in the Journal of Clinical Oncology has evaluated unconventional response patterns during PD-1 inhibitor therapy using immune-related response criteria (irRC) in compa...Journal for ImmunoTherapy of Cancer 2016 4:30Published on: 21 June 2016 - COMMENTARY
How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy
Mounting an immune response sufficient to eradicate a tumor is the goal of modern immunotherapy. Single agent therapies with checkpoint inhibitors or costimulatory molecule agonists are effective only for a sm...Journal for ImmunoTherapy of Cancer 2016 4:31Published on: 21 June 2016 - COMMENTARY
Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule
The Common Rule is a set of ethical principles that provide guidance on the management of human subjects taking part in biomedical and behavioral research in the United States. The elements of the Common Rule ...Journal for ImmunoTherapy of Cancer 2016 4:37Published on: 21 June 2016 - COMMENTARY
Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?
The abscopal effect of radiation describes tumor regression in metastases outside of the field upon treatment of one site, and is mediated by radiation-induced anti-tumor T cells. The ability of radiation to g...Journal for ImmunoTherapy of Cancer 2016 4:29Published on: 17 May 2016 - COMMENTARY
Targetless T cells in cancer immunotherapy
Attention has recently focused on new cancer immunotherapy protocols aiming to activate T cell mediated anti-tumor responses. To this end, administration of antibodies that target inhibitory molecules regulati...Journal for ImmunoTherapy of Cancer 2016 4:23Published on: 19 April 2016 - COMMENTARY
Natural killer cell immunotherapy to target stem-like tumor cells
Advances in cancer immunotherapy are leading to its increasing and successful application for the treatment of solid–tissue cancers. Despite the recent advances there are still significant barriers, in particu...Journal for ImmunoTherapy of Cancer 2016 4:19Published on: 19 April 2016
.png)
No hay comentarios:
Publicar un comentario